Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Karina J. Matissek"'
Autor:
Leif W. Ellisen, A. John Iafrate, Dennis C. Sgroi, Paul E. Goss, Aditya Bardia, Long Phi Le, Dianne M. Finkelstein, Nora Horick, Jessica St. Louis, Gustavo Werutsky, Sahsine Tolunay, Ismet Tasdelen, Pedro Liedke, Henry Gomez, Sahsuvar Gökgöz, Ünal Egeli, Elif Demirdögen, Marcio Debiasi, Yanin Chavarri-Guerra, Arlene Chan, Nuran Beşe, Carlos Barrios, Tanja Badovinac-Crnjevic, Mehrad Tavallai, Allison Macleay, Srinivas Vinod Saladi, Piiha-Lotta Jerevall, Kristofer Patel, Jesse Lee, Andrew Schultz, Zongli Zheng, Sheng Sun, Maristela L. Onozato, Karina J. Matissek
Supplementary Figure S1-S6 and Supplementary Tables S1-S8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::522c72c1019cf2f67606a2b851bf8c63
https://doi.org/10.1158/2159-8290.22531756.v1
https://doi.org/10.1158/2159-8290.22531756.v1
Autor:
Adam Langenbucher, Siang-Boon Koh, Hope S. Rugo, Erica L. Mayer, Lisa A. Carey, Srinivas Vinod Saladi, Lei He, Tiffany A. Traina, Steven J. Isakoff, Vered Stearns, Minetta C. Liu, Michael S. Lawrence, Sridhar Ramaswamy, Nsan Melkonjan, Andrew Schultz, Leif W. Ellisen, Kenneth N. Ross, Karina J. Matissek
Publikováno v:
Koh, S-B, Ross, K, Isakoff, S J, Melkonjan, N, He, L, Matissek, K J, Schultz, A, Mayer, E L, Traina, T A, Carey, L A, Rugo, H S, Liu, M C, Stearns, V, Langenbucher, A, Saladi, S V, Ramaswamy, S, Lawrence, M S & Ellisen, L W 2021, ' RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer ', Clinical Cancer Research, vol. 27, no. 17, pp. 4883-4897 . https://doi.org/10.1158/1078-0432.CCR-21-0714
Clin Cancer Res
Clin Cancer Res
Purpose: While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of refract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47d584ccaf68267da9eb08c33d1fb8ce
https://research-information.bris.ac.uk/en/publications/1e9956ee-f86f-422d-82c9-c3c9149c2fe8
https://research-information.bris.ac.uk/en/publications/1e9956ee-f86f-422d-82c9-c3c9149c2fe8
Autor:
Jessica St. Louis, Sahsuvar Gokgoz, Paul E. Goss, Nuran Bese, Henry L. Gomez, Pedro Er Liedke, Nora Horick, Gustavo Werutsky, Piiha Lotta Jerevall, Karina J. Matissek, Leif W. Ellisen, Allison MacLeay, Dianne M. Finkelstein, Dennis C. Sgroi, Tanja Badovinac-Crnjevic, Ismet Tasdelen, Kristofer Patel, Zongli Zheng, Jesse Lee, Srinivas Vinod Saladi, Elif Demirdogen, A. John Iafrate, Unal Egeli, Maristela L. Onozato, Carlos H. Barrios, Mehrad Tavallai, Arlene Chan, Long P. Le, Aditya Bardia, Sheng Sun, Yanin Chavarri-Guerra, Sahsine Tolunay, Andrew Schultz, Marcio Debiasi
Publikováno v:
Cancer Discovery. 8:336-353
We sought to uncover genetic drivers of hormone receptor–positive (HR+) breast cancer, using a targeted next-generation sequencing approach for detecting expressed gene rearrangements without prior knowledge of the fusion partners. We identified in
Autor:
Mohamed E. Salama, Stephan J. Matissek, Karina J. Matissek, Abood Okal, Margit M. Janát-Amsbury, Robert Price, Carol S. Lim
Publikováno v:
Gene therapy
Inactivation of p53 pathway is reported in more than half of all human tumors and can be correlated to malignant development. Missense mutation in the DNA binding region (DBD) of p53 is the most common mechanism of p53 inactivation in cancer cells. T
Autor:
Sean P. Cornillie, Karina J. Matissek, Carol S. Lim, Stephan J. Matissek, Abood Okal, Thomas E. Cheatham
Publikováno v:
Molecular Pharmaceutics
The use of the tumor suppressor p53 for gene therapy of cancer is limited by the dominant negative inactivating effect of mutant endogenous p53 in cancer cells. We have shown previously that swapping the tetramerization domain (TD) of p53 with the co
Autor:
Karina J. Matissek, Mohanad Mossalam, Andrew S. Dixon, Carol S. Lim, Abood Okal, Philip J. Moos
Publikováno v:
Molecular Pharmaceutics. 10:3922-3933
Because of the dominant negative effect of mutant p53, there has been limited success with wild-type (wt) p53 cancer gene therapy. Therefore, an alternative oligomerization domain for p53 was investigated to enhance the utility of p53 for gene therap
Publikováno v:
Molecular Pharmaceutics. 9:1449-1458
Targeting the tumor suppressor p53 to the mitochondria triggers a rapid apoptotic response as efficiently as transcription-dependent p53. (1, 2) p53 forms a complex with the antiapoptotic Bcl-XL, which leads to Bak and Bax oligomerization resulting i
Publikováno v:
Pharmaceutical research. 31(9)
p53 targeted to the mitochondria is the fastest and most direct pathway for executing p53 death signaling. The purpose of this work was to determine if mitochondrial targeting signals (MTSs) from pro-apoptotic Bak and Bax are capable of targeting p53
Publikováno v:
Molecular pharmaceutics. 10(10)
The tumor suppressor p53 is one of the most studied proteins in human cancer.1-3 While nuclear p53 has been utilized for cancer gene therapy, mitochondrial targeting of p53 has not been fully exploited to date.4,5 In response to cellular stress, p53
The oncoprotein Bcr-Abl stimulates pro-survival pathways and suppresses apoptosis from its exclusively cytoplasmic locale, but when targeted to the mitochondrial compartment of leukemia cells, Bcr-Abl was potently cytotoxic. Therefore, we designed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda9fac631a03cbc62216361d5449488
https://europepmc.org/articles/PMC3529210/
https://europepmc.org/articles/PMC3529210/